Latest Blogs

Aug 15, 2019
Dr. Gil Morgan joins me in a conversation about how our perspectives have been enriched by work, parenthood, and online connections.
Aug 12, 2019
Over 400 attendees and exceptional international faculty members made the 2019 Best of ASCO Lebanon meeting a great success.
Aug 12, 2019
After a breast cancer diagnosis, cancer researcher Dr. Priscila Gonçalves went from "helper" to "helped." She discovered incredible kindness along the way.  
Aug 09, 2019
Planning for our first global meeting, ASCO Breakthrough: A Global Summit for Oncology Innovators, is almost complete.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Jul 02, 2019
Regardless of prognosis, we all must live with the reality that time is fleeting, and none of us have unlimited tomorrows.
Aug 31, 2018
Some reflections on John McCain, mortality, Hamilton, and the story you leave behind. 
Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.

Pages